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In a randomized, controlled trial (n=30), we showed that botulinum toxin injection to the
glabellar region produces a marked improvement in the symptoms of major depression.
We hypothesized that the mood-lifting effect was mediated by facial feedback mecha-
nisms. Here we assessed if agitation, which may be associated with increased dynamic
psychomotor activity of the facial musculature, can predict response to the treatment. To
test this hypothesis, we re-analyzed the data of the scales from our previous study on a
single item basis and compared the baseline scores in the agitation item (item 9) of the
Hamilton Depression Rating Scale (HAM-D) between responders (n=9) and participants
who did not attain response (n=6) among the recipients of onabotulinumtoxinA (n=15).
Responders had significantly higher item 9 scores at baseline [1.56+0.88 vs. 0.33+0.52,
t (13)=3.04, d =1.7, p=0.01], while no other single item of the HAM-D or the Beck Depres-
sion Inventory was associated with treatment response.The agitation score had an overall
precision of 78% in predicting response in a receiver operating characteristic (ROC) analy-
sis (area under the curve, AUC=0.87). These data provide a link between response to
botulinum toxin treatment with a psychomotor manifestation of depression and thereby
indirect support of the proposed facial feedback mechanism of action. Moreover, it sug-
gests that patients with agitated depression may particularly benefit from botulinum toxin
treatment.
Keywords: psychomotor agitation,major depressive disorder, typeA botulinum toxins, randomized controlled trial,
personalized medicine
INTRODUCTION
Botulinum toxin treatment of the face can impact on mood and
affect. After injection of the glabellar region recipients reported an
increase in emotional well-being (1) and a reduction in the lev-
els of negative emotions such as fear and sadness (2). Currently,
five studies have investigated the clinical use of botulinum toxin
injection to the glabellar region in the treatment of depression.
All 10 participants in an open case study experienced remission
of depression or at least marked reduction in its symptoms (3).
Subsequently, in the first randomized, controlled trial (RCT) we
showed that a single treatment of the glabellar region with onabot-
ulinumtoxinA may lead to a strong and sustained alleviation of
major depression symptoms that had not improved sufficiently
through previous antidepressant medication and these findings
were confirmed in two other RCTs (4–6). Improvement in the
symptoms of depression was also observed in a recent open study
(7). Not all patients in our study responded to botulinum toxin
treatment (number needed to treat, NNT= 2.13), however, the
response rate of 60% in the verum group was high, especially
for patients with partly chronic and treatment-resistant depres-
sion. With view to future personalized or stratified approaches
in the management of depression, it would be helpful to identify
predictors of response to botulinum toxin treatment (8). We con-
ducted our study based upon the facial feedback hypothesis, which
implies that negative emotions associated with depression are
maintained and reinforced by proprioceptive afferences from the
facial muscles that express these emotions. The interruption of
this feedback loop by the paralysis of the respective muscles may
accomplish the mood-lifting effect of botulinum toxin. Therefore,
it seems likely that the intervention may be particularly effective
in depressed patients with a high baseline activity of the tar-
geted muscles. Facial features like frown lines or specifically the
“omega melancholicum” and Veraguth’s folds are possible clinical
manifestations of this activity and are associated with agitation,
i.e., a generalized increase in dynamic psychomotor activity in
depression (9).
To test the hypothesis that increased psychomotor activity
in general and in the glabellar region of the face in particular
may predict response of depression to botulinum toxin treat-
ment, we investigated, whether baseline agitation and frown line
severity were associated with treatment outcome measures in
our trial.
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MATERIALS AND METHODS
The original RCT (ClinicalTrials.gov, NCT00934687) was con-
ducted at two centers in Switzerland and Germany as previously
described [open access at http://www.sciencedirect.com/science/
article/pii/S0022395612000386; Ref. (4)]. It had the approval of
the local ethic committees and the regulatory authorities. In brief,
30 eligible, predominantly female outpatients with an average age
of about 50 years with moderate and partly chronic and treatment-
resistant unipolar depression and presence of frown lines gave
informed consent to receive adjunctive injections of either onabot-
ulinumtoxinA (Vistabel®, Botox® Cosmetic, Allergan) or a saline
placebo to the glabellar region. Participants were assessed using
the German versions of the Structured Interview Guide for the
Hamilton Depression Rating Scale with Atypical Depression Sup-
plement (SIGH-ADS) (10), the Beck Depression Inventory (BDI)
self-rating questionnaire, the Clinical Global Impressions Scale
(CGI), and a four-point Clinical Severity Score for Glabellar
Frown Lines (CSS-GFL) (11). Treatment response was defined as
a≥50% reduction after 6 weeks, which was the primary end point
of the trial.
Here, we re-assessed our data in a single item analysis of
the depression scales: in the verum group and separately in the
placebo group, responders and those who did not fulfill the
response criteria were compared for the collected baseline char-
acteristics including single item scores of the HAM-D scale and
the BDI applying Student’s t -tests or Welch-test for continu-
ous, and Fisher’s exact tests for categorical variables. All tests
were two-sided and variance is reported as standard deviation.
Effect sizes are reported as Cohen’s d. A receiver operating char-
acteristic (ROC) curve analysis was performed to estimate the
sensitivity, specificity, and overall precision of the baseline HAM-
D agitation item (item 9) score (0=“none,” 1=“fidgetiness,”
2=“playing with hands, hair, etc.,” 3=“moving about, cannot
sit still,” and 4=“hand wringing, nail biting, hair pulling, biting
of lips”) in predicting treatment response. According to the deter-
mined cut-off, participants were classified into a lower agitation
(≤1, LA) and a higher agitation (≥2, HA) group. For a more
precise assessment of glabellar frown line severity, we introduced
intermediate steps to the CSS-GFL and ranked all 30 participants
of the study according to their individual frown line severity at
maximum frowning (1= strongest, 30=weakest frown line). Test
results with unadjusted p-values of ≤0.05 were considered sig-
nificant. Statistical analyses were conducted using SPSS 19.0 for
Windows.
RESULTS
The participants who received onabotulinumtoxinA treatment
(n= 15) and were responders (n= 9) had significantly higher
baseline scores in the agitation item of the HAM-D scale
than participants who did not fulfill the response criterion
[n= 6; 1.56± 0.88 vs. 0.33± 0.52, t (13)= 3.04, d = 1.7, p= 0.01,
Figure 1A]. Response was not associated with baseline scores
of any other HAM-D item. Hence, in the BDI, which does not
assess agitation, no baseline score of any item was associated with
response (Table S1 in Supplementary Material). Baseline agita-
tion scores did not differ significantly between the verum and the
placebo group [1.07± 0.96 vs. 0.87± 1.06, t (28)= 0.54, d = 0.2,
FIGURE 1 | Higher baseline agitation in responders. Responders (Res.±,
n=9) had significantly higher baseline scores in the agitation item (item 9)
of the HAM-D than participants who did not fulfill the response criterion
[Res.−, n=6; 1.56±0.88 vs. 0.33± 0.52, t (13) =3.04, d =1.7, p=0.01**
(A)]. Participants with higher agitation scores at baseline (HA) tended to
have a greater improvement in the HAM-D17 score (∆ HAM-D17) compared
to those with lower agitation scores [LA, n=10; 14.2±1.92 vs. 8.0±9.37,
w (13) = 2.01, d =0.92, p=0.07 (B)].
p= 0.59] and were not associated with response in the placebo
group [1.0± 1.41 vs. 0.85± 1.07, t (13)= 0.18, d = 0.2, p= 0.86].
An ROC curve analysis revealed that the baseline agitation score
was a good predictor of response (Figure 2A): the area under the
curve (AUC) was 0.87 (95% CI= 0.69–1.05, p= 0.02). With a
sensitivity of 100% (1.0, 95% CI= 0.54–1.0) and a specificity of
56% (0.56, 95% CI= 0.21–0.86), a cut-off between 1 and 2 (1.5)
achieved the best overall precision (78%). Accordingly, all patients
in the verum group with a baseline agitation score of ≥2 (HA,
n= 5) but only a minority of those with a baseline agitation score
of≤1 (LA,n= 10) attained response (100 vs. 40%, risk ratio= 2.5,
95% CI= 1.17–5.34, p= 0.04, Table 1). HA participants tended to
have a greater improvement in the HAM-D17 total score from
baseline to the visit after 6 weeks (∆ HAM-D17) compared to
LA participants [14.2± 1.92 vs. 8.0± 9.37, w(13)= 2.01, d = 0.92,
p= 0.07, Figure 1B] and there was a trend toward a correlation
of baseline agitation scores with∆ HAM-D17 (r = 0.45, p= 0.10,
Figure 2B).
There was only a non-significant reduction in the agitation
score from baseline to the visit after 6 weeks (∆ HAM-D-9) in
the verum group [from 1.07± 0.96 to 0.67± 1.11, t (14)= 1.57,
p= 0.14], which was driven by the HA sub-group [from 2.2± 0.45
to 1.2± 1.11, t (4)= 2.24, p= 0.09].
Baseline severity of glabellar frown lines as a possible
facial correlate of psychomotor activity was not associated
with response. Neither the original CSS-GFL [2.22± 0.44 vs.
2.17± 0.41, t (13)= 0.254, d = 0.12, p= 0.81] nor the modified
version with the newly introduced intermediate steps [2.22± 0.51
vs. 2.0± 0.77, t (13)= 0.68, d = 0.34, p= 0.51] nor the average
rankings [15.67± 7.09 vs. 21.33± 9.73, t (13)= 1.31, d = 0.66,
p= 0.21] differed between responders and those who did not
respond in the verum group. The change in the CSS-GFL between
baseline and the visit after 6 weeks (∆ CSS-GFL) was similar
between the two groups [0.89± 0.33 vs. 0.83± 0.41, t (13)= 0.29,
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FIGURE 2 | Prediction of response by baseline agitation. ROC curve for
the baseline scores in the agitation item of the HAM-D as a predictor of
response [AUC=0.87, 95% CI=0.69–1.05, p=0.02 (A)] correlation of
baseline agitation scores with improvement in the HAM-D17 total score (∆
HAM-D17) from baseline to the visit after 6 weeks [r = 0.45, p=0.10 (B)].
Table 1 | Association of agitation with response.
Agitation
Response HA (%) LA (%)
+ 5 (100) 4 (40)
− 0 (0) 6 (60)
Fisher’s exact test p=0.04, risk ratio=2.5, 95% CI=1.17–5.34.
Distribution of the patients of the verum group according to baseline agitation
(HA, LA) and response. All HA participants are responders, indicating a positive
predictive value of higher agitation at baseline for response to onabotulinumtoxinA
treatment. Conversely, lower agitation at baseline does not preclude response.
d = 0.16, p= 0.78]. However, we found a correlation of the base-
line score in the modified version of the CSS-GFL and of the
baseline rank of frown line severity with improvement in the
HAM-D17 total score from baseline to the visit after 16 weeks
(r = 0.51, p= 0.05; r =−0.68, p= 0.01). These correlations were
not significant at the primary end point after 6 weeks (r = 0.31,
p= 0.26; r =−0.46, p= 0.08). Glabellar frown line severity was
not associated with agitation (p≥ 0.08).
DISCUSSION
Using an RCT design, we previously demonstrated that treatment
of the glabellar region with onabotulinumtoxinA can reduce the
symptoms of major depression (4).
The mechanisms underlying this clinical effect are unknown.
However, a facial feedback mechanism is supported by other stud-
ies that show effects of botulinum toxin treatment on emotional
perception (12–14), as well as by experiments in which facial mus-
cle activity was influenced by other means (15–17). Accordingly,
we hypothesized that clinical improvement in depression would
most likely be mediated by a modification of direct proprioceptive
feedback induced by a reduction of primarily increased facial mus-
cle activity. Thus, patients with high base levels of glabellar muscle
activity may benefit more from the treatment than patients with
low base levels of such activity. High activation levels may mani-
fest in facial features like frown lines and specifically the “omega
melancholicum,” which is associated with psychomotor agitation
in depression (9). In support of our hypothesis, we showed that
responders to botulinum toxin treatment had higher agitation
levels at baseline than participants who did not respond to the
treatment and that a higher baseline level of agitation, as measured
by the item 9 of the HAM-D scale (>1), had a good positive pre-
dictive value referring to response to botulinum toxin treatment
in our study (18). However, a lower baseline level of agitation
(≤1) did not preclude response. These findings were specific to
agitation as no other single item was associated with response.
Agitation was associated with response only in the verum but not
in the placebo group and, therefore, not a general indicator of a
better outcome in our sample. Association of psychomotor symp-
toms with treatment outcome has been observed before; however,
these observations were inconsistent (19). Floor effects in the LA
participants may explain the non-significant ∆ HAM-D-9. Some
reduction in the item 9 score after treatment was conferred by the
HA patients. This suggests that agitation was probably rather a
psychomotor state marker of depression than a psychomotor trait
of the respective individuals.
The described association of agitation with response is in
line with facial feedback as a possible mechanism underlying the
observed clinical improvement, because it links the improvement
to a psychomotor endophenotype of depression that may com-
prise facial muscle activation patterns targeted by the treatment.
At the same time, the retrospective identification of a predictor for
response within the verum group that is mechanistically plausible
may be regarded as an argument against a major role of placebo
effects.
We found only a weak link between glabellar frown line sever-
ity at baseline with clinical improvement in depression. Although
frown line severity may not necessarily directly reflect the actual
facial muscle activity, it is probably influenced by an individual’s
facial psychomotor history. Thus, this link may also support a facial
feedback mechanism of action. The ability to produce a moderate
frown line at maximum frowning was an inclusion criterion in
our study (4). This may have led to a reduction in the variability
of frown line severity in our sample and to an underestimation of
its correlation with improvement in depression. In another RCT,
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frown line severity was not an inclusion criterion and in this trial
there was a trend toward association of reduction in frown line
severity and improvement in depression (5). The “omega melan-
cholicum” is associated with agitation in depression (9). However,
we did not observe association of frown line severity with agitation
in the participants of our study. In future studies, a more thorough
and more direct assessment of facial muscle activity should be
applied: facial electromyography and standardized video record-
ings, which can be evaluated using, e.g., the facial action coding
system (FACS) (20) may be used to investigate if facial psychomo-
tor features can predict response of depression to botulinum toxin
treatment and customize its dosage and injection sites.
A limitation of the present study is the rather low number
(n= 15) of participants. Thus it cannot be excluded, that the
observed association of agitation with response is a statistical type
I error. Driven by the hypothesis that a psychomotor phenotype
with increased activity may show a better response, we investigated
primarily the association of response and agitation and frown line
severity. We acknowledge that a higher response rate in partic-
ipants with higher agitation levels at baseline was not a stated
prediction of the original study. Thus, the association of agita-
tion with response would not remain significant, if we applied a
Bonferroni correction for the multiple comparisons we did when
we looked at the other single items of the HAM-D and the BDI
scales and the other baseline variables to assess the specificity of the
observed association. Therefore, our observation needs to be con-
firmed in further and larger studies. In the meantime, we had the
opportunity to verify our finding in another recent RCT on botu-
linum toxin in the treatment of depression that used the HAM-D
scale (6). In this trial, only one of the 28 recipients of botulinum
toxin injections had an HA score at the baseline of the treatment
period and she turned out to be a responder. One may specu-
late that the relative lack of HA subjects could partly explain the
slightly lower overall response rate in this study.
The identification of agitation as a predictor of response may
be helpful in the development of stratified medicine approaches
in the treatment of depression. Notably, our patients did not have
overt agitated depression but only varied in their agitation scores
in the HAM-D scale. Hence, none of the participants scored 4
in the agitation item. It is possible that patients with clinical
agitated depression may respond particularly well to botulinum
toxin treatment, which corresponds to our personal clinical expe-
rience. Moreover, our findings suggest that glabellar injection of
botulinum toxin may also be effective as a treatment of other psy-
chiatric disorders associated with negative emotions and increased
psychomotor activity.
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